ORR overall response rate, DLT dose limiting toxicity, MTD maximum tolerated dose, CR complete response, PR partial response, SD stable disease, PFS progression free survival, OS overall survival, CBR clinical benefit rate (PR rate+ rate of SD at least 6 months), BC breast cancer, mCRPC metastatic castrate resistant prostate cancer, ZA zoledronic acid, SCLC small cell lung cancer, NSCLC non-small cell lung cancer, RCC renal cell carcinoma, MM multiple myeloma, MMP matrix metalloproteinase, ETA endothelin-A. This evidence concerns the gene EDNRA and small cell lung carcinoma.